Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 22, 2024
Daily News
January 22, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- MHLW Urges Prioritized Delivery of Drugs under Shipment Control to Ishikawa
January 22, 2024
- Japan Needs National Efforts to Boost Biosimilar Production: Kameda Chief Pharmacist
January 22, 2024
- Requests Raised on LLP Coverage Rule, Supply Issue: Chuikyo Public Hearing
January 22, 2024
- PMDA Reviewing Safety Risks for 12 Drugs including Kinase Inhibitors
January 22, 2024
- Moderna Japan Files 0.5 mL Vial Formulation for Spikevax
January 22, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…